These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27429314)

  • 1. In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
    Sfeir JG; Montori VM
    Ann Intern Med; 2016 Jul; 165(2):JC2. PubMed ID: 27429314
    [No Abstract]   [Full Text] [Related]  

  • 2. Canagliflozin use in Type I diabetes mellitus.
    Guthrie R
    Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
    Novik A V; García B C; Oliva I D
    Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
    Adachi J; Inaba Y; Maki C
    Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes.
    González Sanchidrián S; Gómez-Martino Arroyo JR; Labrador Gómez PJ
    Med Clin (Barc); 2017 Feb; 148(4):e19-e20. PubMed ID: 28041622
    [No Abstract]   [Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes.
    Harati H; Sharma V; Motazedi A
    J Diabetes; 2016 Jan; 8(1):165. PubMed ID: 26211700
    [No Abstract]   [Full Text] [Related]  

  • 7. Canagliflozin induced diabetic ketoacidosis.
    Diéguez-Felechosa M; Suárez-Gutiérrez L
    Endocrinol Nutr; 2016 Oct; 63(8):430-1. PubMed ID: 27346596
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Dhatariya K
    Diabetes Care; 2016 Jan; 39(1):e18. PubMed ID: 26696665
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Ou HY; Karnchanasorn R; Chuang LM; Chiu KC
    Diabetes Care; 2015 Nov; 38(11):e198. PubMed ID: 26494820
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
    Erondu N; Desai M; Ways K; Meininger G
    Diabetes Care; 2016 Jan; 39(1):e19. PubMed ID: 26696666
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Ramirez Tello EM; Orellana-Barrios MA; Nugent K
    Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
    [No Abstract]   [Full Text] [Related]  

  • 12. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
    Clement M; Senior P
    Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
    [No Abstract]   [Full Text] [Related]  

  • 13. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
    Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
    Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
    Henry RR; Thakkar P; Tong C; Polidori D; Alba M
    Diabetes Care; 2015 Dec; 38(12):2258-65. PubMed ID: 26486192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic Ketoacidosis Among Patients Treated With Continuous Subcutaneous Insulin Infusion.
    Dogan ADA; Jørgensen UL; Gjessing HJ
    J Diabetes Sci Technol; 2017 May; 11(3):631-632. PubMed ID: 27595713
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin dose requirement in diabetic ketoacidosis.
    Taylor R
    Diabet Med; 2012 Jan; 29(1):153; author reply 153-4. PubMed ID: 21812813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.